A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)
A Double-Blind, Double Dummy, Randomized, Placebo-Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of MK1809 in Healthy Young Volunteers
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Part 1:
- Nonsmoker for at least 6 months
- Body Mass Index (BMI) less than or equal to 29 kg/m2
- In overall good health
Part 2:
- Body Mass Index (BMI) greater than 18kg/m2 and less than or equal to 35kg/m2
- In overall good health (patients with hypertension and/or hyperlipidemia are accepted)
Exclusion Criteria:
Part 1:
- History of any cardiovascular disease or any clinically significant family history of cardiac arrhythmias or conduction abnormalities at an age less than 60 years
- History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder
- History of cancer
- Clinically significant history of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines)
- Active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety)
- History of asthma, severe wheezing, COPD, or other pulmonary disease
- Individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties
- Major surgery, donated blood or participated in another investigational drug(s) trial within 30 days
- Illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years)
- Nitrate therapy within 4 weeks
- History of significant drug allergy or history of food allergies
Part 2
- History of any clinically significant cardiac or cardiovascular disease (other than hypertension)
- History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder
- History of cancer
- History of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines)
- Active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety)
- History of asthma, severe wheezing, COPD, or other pulmonary disease
- Individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties
- Illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years)
- Surgery, significant blood loss, donated blood, or participated in another investigational drug(s) trial within 30 days
- Nitrate therapy within 4 weeks
- History of significant drug allergy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Part 1 A-1
Part 1; Panel A; Sequence 1: 2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 1 A-2
Part 1; Panel A; Sequence 2: Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809 |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 1 A-3
Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809
|
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 1 A-4
Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo
|
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 1 A-5
Part 1; Panel A; Sequence 5: Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809 |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 1 B-1
Part 1; Panel B; Sequence 1: 5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food |
single oral doses of MK1809
Placebo to MK1809
|
実験的:Part 1 B-2
Part 1; Panel B; Sequence 2: 5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 1 B-3
Part 1; Panel B; Sequence 3: 5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
|
実験的:Part 1 B-4
Part 1; Panel B; Sequence 4: Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 1 B-5
Part 1; Panel B; Sequence 5: Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 2 C-1
Part 2; Panel C; Sequence 1: 50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 2 C-2
Part 2; Panel C; Sequence 2: 50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809 |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 2 C-3
Part 2; Panel C; Sequence 3: Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 2 C-4
Part 2; Panel C; Sequence 4: 50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809 |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
実験的:Part 2 C-5
Part 2; Panel C; Sequence 5: Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809 |
single oral doses of MK1809
single oral doses of 100 mg Losartan
他の名前:
Placebo to MK1809
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Part I: Area under the plasma concentration (AUC) versus time curve in healthy adult male subjects in the fasted state
時間枠:Through 32 hours postdose
|
Through 32 hours postdose
|
Part 1: Trough plasma concentration in healthy adult male subjects in the fasted state
時間枠:24 hours postdose
|
24 hours postdose
|
Part 2: Safety and tolerability of rising single oral doses of MK1809 in adult hypertensive patients based on an assessment of clinical and laboratory adverse experiences
時間枠:Duration of study and up to 14 days after administration of the last dose of study drug
|
Duration of study and up to 14 days after administration of the last dose of study drug
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Part 1: Area under the plasma concentration (AUC) versus time curve resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)
時間枠:24 hours postdose
|
24 hours postdose
|
Part 1: Maximum concentration of drug in the plasma (Cmax) resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)
時間枠:Through 32 hours postdose
|
Through 32 hours postdose
|
Part 1: Number of clinical and laboratory adverse experiences (AEs) to assess safety and tolerability
時間枠:Duration of study and up to 14 days after administration of the last dose of study drug
|
Duration of study and up to 14 days after administration of the last dose of study drug
|
Part 2: Area under the plasma concentration (AUC) versus time curve of the E3174 metabolite
時間枠:Through 32 hours postdose
|
Through 32 hours postdose
|
Part 2: Trough plasma concentration of the E3174 metabolite
時間枠:Through 32 hours postdose
|
Through 32 hours postdose
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 1809-001
- MK1809-001
- 2009_703
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。